Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 42Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Lymphoma 3Breast Diseases 3Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Hematologic Neoplasms 2Glioma 2Carcinoma, Renal Cell 2Breast Neoplasm Female 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Venous Thromboembolism 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1

Interventions

enzalutamide 33Abiraterone Acetate 29apalutamide 26Prednisone 26Radiotherapy 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 22Radiosurgery 19darolutamide 18Docetaxel 17Gonadotropin-Releasing Hormone 16acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 13gallium 68 PSMA-11 12bicalutamide 12Specimen Handling 12Radiotherapy, Intensity-Modulated 12abiraterone 11Radiation 11pembrolizumab 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Triptorelin Pamoate 8Standard of Care 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × palbociclib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡